Olivier Bory

Olivier Bory

Auto-generated profile, based on publicly available information

Olivier Bory

Department of internal medicine, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris, 178 rue des Renouillers, 92700 Colombes, France; Université Paris Cité, ECEVE, UMR 1123, Inserm, 10 boulevard de Verdun, 75010 Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
RCRichard Chocron
Richard Chocron
BDBaptiste Duceau
Baptiste Duceau
NGNicolas Gendron
Nicolas Gendron
NENacim Ezzouhairi
Nacim Ezzouhairi
LKLina Khider
Lina Khider
DSDavid M. Smadja
David M. Smadja

8 April 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
DSDavid M Smadja
David M Smadja
APAurélien Philippe
Aurélien Philippe
OBOlivier Bory
Olivier Bory
NGNicolas GENDRON
Nicolas GENDRON
ABAgathe Beauvais
Agathe Beauvais
RCRichard Chocron
Richard Chocron
Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with vascular inflammation and endothelial injury. Objectives Correlate circulating angiogenic markers VEGF‐A, PlGF and FGF‐2 to in‐hospital mortality in COVID‐19 adult patients. Methods Consecutive ambulatory and hospitalized patients with COVID‐19 infection were enrolled. VEGF‐A, PlGF and FGF‐2 were measured in each patient ≤48 h following admission. Results Study enrolled 237 patients with suspected COVID‐19: 208 patients had a positive diagnostic for COVID‐19 of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF‐A, PlGF and FGF‐2 significantly increase with the severity of the disease (p<0.001). Using a logistic regression model we found a significant association between the increase of FGF‐2 or PlGF and mortality (OR 1.11, 95% CI [1.07–1.16], p<0.001 for FGF‐2 and OR 1.07 95% CI [1.04–1.10], p<0.001 for PlGF) while no association were found for VEGF‐A levels. ROC curve analysis was performed and we identified PlGF above 30 pg/mL as the best predictor of in‐hospital mortality in COVID‐19 patients. Survival analysis for PlGF confirmed its interest for in‐hospital mortality prediction, by using a Kaplan‐Meier survival curves (p=0.001) and a Cox proportional hazard model adjusted to age, body mass index, D‐dimer and CRP (3.23 95% CI [1.29–8.11], p=0.001). Conclusion Angiogenic factor PlGF is a relevant predictive factor for in‐hospital mortality in COVID‐19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID‐19.

20 April 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
RCRichard Chocron
Richard Chocron
VGVincent Galand
Vincent Galand
JCJoffrey Cellier
Joffrey Cellier
NGNicolas GENDRON
Nicolas GENDRON
TPThibaut Pommier
Thibaut Pommier
TIthe Critical COVID‐19 France Investigators
the Critical COVID‐19 France Investigators
Background: Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with thrombotic outcomes with coagulation and endothelial disorders. Based on that, several anticoagulation guidelines have been proposed. We aimed to determine whether anticoagulation therapy modifies the risk of developing severe COVID‐19. Methods and Results: Patients with COVID‐19 initially admitted in medical wards of 24 French hospitals were included prospectively from February 26 to April 20, 2020. We used a Poisson regression model, Cox proportional hazard model, and matched propensity score to assess the effect of anticoagulation on outcomes (intensive care unit admission or in‐hospital mortality). The study enrolled 2878 patients with COVID‐19, among whom 382 (13.2%) were treated with oral anticoagulation therapy before hospitalization. After adjustment, anticoagulation therapy before hospitalization was associated with a better prognosis with an adjusted hazard ratio of 0.70 (95% CI, 0.55–0.88). Analyses performed using propensity score matching confirmed that anticoagulation therapy before hospitalization was associated with a better prognosis, with an adjusted hazard ratio of 0.43 (95% CI, 0.29–0.63) for intensive care unit admission and adjusted hazard ratio of 0.76 (95% CI, 0.61–0.98) for composite criteria intensive care unit admission or death. In contrast, therapeutic or prophylactic low‐ or high‐dose anticoagulation started during hospitalization were not associated with any of the outcomes. Conclusions: Anticoagulation therapy used before hospitalization in medical wards was associated with a better prognosis in contrast with anticoagulation initiated during hospitalization. Anticoagulation therapy introduced in early disease could better prevent COVID‐19–associated coagulopathy and endotheliopathy, and lead to a better prognosis.

23 March 2026 in Health Policy
Verified
Journal Article
Open access
OBOlivier Bory
Olivier Bory
PMPhilippe Martin
Philippe Martin
EAElisabeth Aslangul
Elisabeth Aslangul
JKJoelle Kivits
Joelle Kivits
MMMorgane Michel
Morgane Michel
The term "outpatient" refers to a patient attending hospital without overnight admission. Despite its importance in health service delivery, the term seems to be used inconsistently in the literature, hindering analysis and comparability. To describe the use of outpatient in scientific and grey literature, identify patterns of incorrect usage, and propose an exploratory nomenclature. We conducted a scoping review of scientific (Medline, 1952-2025) and grey literature (>2019). Eligible references included the term "outpatient" or described outpatient pathways within a hospital. The primary outcome was correct use of the formal definition. Multivariable regression explored patterns of incorrect use. A qualitative analysis informed the development of a proposed nomenclature. Of 1624 scientific references, 984 were included; incorrect use occurred in 47%, as misuse, non-use, or mixed-use. Pattern of incorrect use were observed in relation to articles published before 2013, and without manual tags/MeSH terms. Grey literature showed similar patterns across countries and institutions. Inductive analysis yielded a four-category nomenclature: unscheduled, scheduled, coordinated, and supervised. This study highlights the widespread incorrect use of the term "outpatient" across countries, journals, and institutions. Greater conceptual clarity and the use of a shared nomenclature may support more reliable descriptions of hospital activity, improve cross-country comparability, and inform evidence-based health policy analysis.

1 January 2025 in Case Reports in Dentistry
Verified
Journal Article
Open access
FTFrançoise Tilotta
Françoise Tilotta
HVHadrien Le Vayer
Hadrien Le Vayer
OBOlivier Bory
Olivier Bory
CMCaroline Morbieu
Caroline Morbieu
LRLoredana RADOI
Loredana RADOI
A 41‐year‐old female patient in apparent good health presented to the dental emergency department with a 6‐week history of painless, nonpruritic left facial swelling, and dotted with purplish patches. She had consulted different physicians and dentists and received several ineffective treatments. After ruling out an oral cause, standard blood tests were initially prescribed. They showed an isolated elevation of creatine phosphokinase (CPK). Muscular weakness of the left arm and leg, pain on mobilization of the left thigh, and erythematous plaques on the left body then appeared. Infectious, granulomatous, and autoimmune diseases were investigated. Magnetic resonance imaging (MRI) showed diffuse muscle infiltration, suggestive of myositis. Myositis‐specific dot immunoassay identified antinuclear matrix protein 2 (NXP2) autoantibodies, enabling the diagnosis of dermatomyositis. The inaugural orofacial manifestations of dermatomyositis can be confused with pathologies of dental cause, such as cellulitis. In the absence of local warning signs, oral health professionals must consider a systemic etiology and rapidly refer the patient to avoid patient wandering.

15 September 2026
Verified
Thesis
Closed access
OBOlivier Bory
Olivier Bory
La médecine ambulatoire hospitalière (MAH) regroupe les prises en charge réalisées à l’hôpital sans nuitée. Bien qu’elle représente une part importante de l’activité hospitalière, elle reste insuffisamment identifiée dans les données d’activité hospitalières. Les usages hétérogènes des termes « ambulatoire » et « outpatient », ainsi que la fragmentation des systèmes médico-administratifs, limitent sa visibilité et entravent l’analyse de sa contribution à la performance des systèmes de santé. Dans le cadre conceptuel de l’Organisation mondiale de la santé, la performance repose sur l’articulation de quatre fonctions (gouvernance, financement, création de ressources, prestation de services) au service de trois objectifs : amélioration de la santé, réactivité aux attentes des usagers et équité de la contribution financière. L’absence de nomenclature de la MAH constitue un premier obstacle à son évaluation au regard de ces objectifs. Un second obstacle est l’absence d’un cadre analytique permettant de comprendre comment la MAH contribue à la performance Cette thèse vise à clarifier conceptuellement la MAH, à en proposer une nomenclature pour permettre l’analyse de sa contribution à la performance du système de santé. Elle vise à comprendre sa contribution par l’analyse des fonctions du système de santé à l’échelle d’un hôpital de jour (HDJ) à travers trois angles : l’accès à l’expertise hospitalière perçu par les médecins généralistes, l’accès à la vaccination pour des patients à risque, et l’impact budgétaire pour l’hôpital de la création d’un parcours en HDJ destiné à des patients autonomes ne nécessitant pas de surveillance infirmière dédiée (« salon ambulatoire »). Cinq volets composent ce travail. Une revue de portée analyse les usages du terme « outpatient » dans la littérature internationale. À partir des références l’employant conformément à la définition, une nomenclature inductive est élaborée puis confrontée aux bases médico-administratives françaises afin d’en tester l’applicabilité. Trois études empiriques sont ensuite conduites dans un HDJ partagé entre six spécialités : une étude qualitative par entretiens auprès de médecins généralistes, une évaluation avant/après d’un programme infirmier sur la couverture vaccinale antipneumococcique, et une analyse d’impact budgétaire, du point de vue de l’hôpital, d’un parcours « salon ambulatoire » dédié à des patients autonomes venant en HDJ, ne nécessitant pas de surveillance infirmière. Les résultats montrent que la MAH constitue un ensemble d’activités hétérogènes parfois identifiées et nommées différemment. Il aura été possible de définir une nomenclature et un cadre d’analyse fondé sur des critères organisationnels de lieu et de temps du soin. La nomenclature proposée permet une classification exhaustive des prises en charge hospitalières sans nuitée et améliore leur analyse. Les études empiriques suggèrent que la MAH peut contribuer à la performance du système de santé en facilitant la coordination ville–hôpital, en intégrant des programmes de vaccination systématisé et en adaptant l’allocation des ressources hospitalière en fonction des besoins des patients. En articulant la clarification conceptuelle, le cadre d’analyse et l’étude de la contribution à la performance, cette thèse permet de comprendre et de discuter des implications de la MAH pour l’amélioration de la santé de la population.